Cutaneous adverse events following the COVID-19 vaccination: a case series of 30 Japanese patients and a review of 93 Japanese studies

Cutaneous adverse events following the COVID-19 vaccination: a case series of 30 Japanese patients and a review of 93 Japanese studies - Cutaneous adverse events following the COVID-19 vaccination: a case series of 30 Japanese patients and a review of 93 Japanese studies

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000053107

Enrollment

Registered

2023-12-14

Start date

2021-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cutameous adverse events to COVID-19 vaccination

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients with skin manifestations within 30 days or less following the COVID-19 vaccination

Exclusion criteria

Exclusion criteria: All patients included in our study were diagnosed based on clinical and/or histopathological evaluations, and all other possible differential diagnoses were excluded.

Design outcomes

Primary

Measure	Time frame
This study was approved by the Medical Ethics Committee of Kagoshima City Hospital, Kagoshima, Japan (No 2021-47). A case series analysis was conducted at our hospital, and all patients with skin manifestations within 30 days or less following the COVID-19 vaccination were enrolled. All patients included in our study were diagnosed based on clinical and/or histopathological evaluations, and all other possible differential diagnoses were excluded. Next, we extracted cutaneous AEs induced by COVID-19 vaccines reported to the Ministry of Health, Labor, and Welfare,3 categorized them, and counted the number of cases. Finally, we performed a literature review by searching PubMed, Google Scholar, and Ichushi Web Library databases for articles about Japanese cases of cutaneous manifestations after COVID-19 vaccination between April 2021 and March 2023 written in English or Japanese. We considered cases or studies describing patients with new-onset or pre-existing skin disease following COVID-19 vaccination eligibility and excluded studies with unknown vaccine types and insufficient diagnoses. Results are expressed as mean SD. Comparisons between the two groups were performed using Welch s t-tests. Differences with p 0.05 were considered significant.	—

Measure

Time frame

This study was approved by the Medical Ethics Committee of Kagoshima City Hospital, Kagoshima, Japan (No 2021-47). A case series analysis was conducted at our hospital, and all patients with skin manifestations within 30 days or less following the COVID-19 vaccination were enrolled. All patients included in our study were diagnosed based on clinical and/or histopathological evaluations, and all other possible differential diagnoses were excluded. Next, we extracted cutaneous AEs induced by COVID-19 vaccines reported to the Ministry of Health, Labor, and Welfare,3 categorized them, and counted the number of cases. Finally, we performed a literature review by searching PubMed, Google Scholar, and Ichushi Web Library databases for articles about Japanese cases of cutaneous manifestations after COVID-19 vaccination between April 2021 and March 2023 written in English or Japanese. We considered cases or studies describing patients with new-onset or pre-existing skin disease following COVID-19 vaccination eligibility and excluded studies with unknown vaccine types and insufficient diagnoses. Results are expressed as mean SD. Comparisons between the two groups were performed using Welch s t-tests. Differences with p 0.05 were considered significant.

—

Countries

Japan

Contacts

Public ContactAtsunori Baba

Kagoshima City Hospital Department of Dermatology,

baba-a16@kch.kagoshima.jp0992307000

Outcome results